A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosis

Neurology

Volumn 83, Issue 17, 2014, Pages 1492-1499

  Dickens, Alex M ^a,b   Larkin, James R ^a   Griffin, Julian L ^d   Cavey, Ana ^a   Matthews, Lucy ^a   Turner, Martin R ^a   Wilcock, Gordon K ^c   Davis, Benjamin G ^b   Claridge, Timothy D W ^b   Palace, Jacqueline ^d   Anthony, Daniel C ^a   Sibson, Nicola R ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METABOLOMICS; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NUCLEAR MAGNETIC RESONANCE; PARTIAL LEAST SQUARES REGRESSION; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; DISCRIMINANT ANALYSIS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; RECEIVER OPERATING CHARACTERISTIC; REPRODUCIBILITY;

ADULT; AGED; ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; BIOMARKERS; CASE-CONTROL STUDIES; COHORT STUDIES; DISCRIMINANT ANALYSIS; FEMALE; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; METABOLOMICS; MIDDLE AGED; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; REPRODUCIBILITY OF RESULTS; ROC CURVE;

EID: 84925964860     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000905     Document Type: Article

References (28)

1. Jia Y, Wu T, Jelinek CA, et al. Development of protein biomarkers in cerebrospinal fluid for secondary progressive multiple sclerosis using selected reaction monitoring mass spectrometry (SRM-MS). Clin Proteomics 2012;9:9.
2. Menge T, Weber MS, Hemmer B, et al. Disease-modifying agents for multiple sclerosis: recent advances and future prospects. Drugs 2008;68:2445-2468.
3. Rieckmann P, Smith KJ. Multiple sclerosis: more than inflammation and demyelination. Trends Neurosci 2001; 24:435-437.
4. Jones JL, Coles AJ. New treatment strategies in multiple sclerosis. Exp Neurol 2010;225:34-39.
5. Hauser SL, Chan JR, Oksenberg JR. Multiple sclerosis: prospects and promise. Ann Neurol 2013;74:317-327.
6. Holmes E, Foxall PJ, Nicholson JK, et al. Automatic data reduction and pattern recognition methods for analysis of 1H nuclear magnetic resonance spectra of human urine from normal and pathological states. Anal Biochem 1994;220:284-296.
7. Lindon J, Holmes E, Nicholson J. Metabonomics in pharmaceutical R & D. FEBS J 2007;274:1140-1151.
8. Salek RM, Xia J, Innes A, et al. A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. Neurochem Int 2010;56:937-947.
9. Lindon JC, Holmes E, Nicholson JK. Pattern recognition methods and applications in biomedical magnetic resonance. Prog Nucl Magn Reson Spectrosc 2001;39:1-40.
10. Griffin JL, Anthony DC, Campbell SJ, et al. Study of cytokine induced neuropathology by high resolution proton NMR spectroscopy of rat urine. FEBS Lett 2004;568: 49-54.
11. 't Hart BA, Vogels JT, Spijksma G, Brok HP, Polman C, van der Greef J. H-1-NMR spectroscopy combined with pattern recognition analysis reveals characteristic chemical patterns in urines of MS patients and non-human primates with MS-like disease. J Neurol Sci 2003;212:21-30.
12. McDonald W, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
13. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005;58:840-846.
14. Waterman C, Currie R, Cottrell L, et al. An integrated functional genomic study of acute phenobarbital exposure in the rat. BMC Genomics 2010;11:9.
15. Tomasi G, van den Berg F, Andersson C. Correlation optimized warping and dynamic time warping as preprocessing methods for chromatographic data. J Chemom 2004;18:231-241.
16. Fan WMT. Metabolite profiling by one- and twodimensional NMR analysis of complex mixtures. Prog Nucl Magn Reson Spectrosc 1996;28:161-219.
17. Wishart DS, Tzur D, Knox C, et al. HMDB: the human metabolome database. Nucleic Acids Res 2007; 35:D521-D526.
18. Wishart DS, Knox C, Guo AC, et al. HMDB: a knowledgebase for the human metabolome. Nucleic Acids Res 2009;37:D603.
19. Scalfari A, Neuhaus A, Degenhardt A, et al. The natural history of multiple sclerosis, a geographically based study 10: relapses and long-term disability. Brain 2010;133: 1914-1929.
20. Whitaker JN, Kachelhofer RD, Bradley EL, et al. Urinary myelin basic protein-like material as a correlate of the progression of multiple sclerosis. Ann Neurol 1995;38: 625-632.
21. Whitaker JN, McKeehan A, Freeman DW. Monoclonal and polyclonal antibody responses to the myelin basic protein epitope present in human urine. J Neuroimmunol 1994;52:53-60.
22. OttM, Demisch L, EngelhardtW, Fischer PA. Interleukin-2, soluble interleukin-2-receptor, neopterin, L-tryptophan and beta 2-microglobulin levels in CSF and serum of patients with relapsing remitting or chronic progressive multiple sclerosis. J Neurol 1993;241:108-114.
23. Giovannoni G, Lai M, Kidd D, et al. Daily urinary neopterin excretion as an immunological marker of disease activity in multiple sclerosis. Brain 1997;120:1-13.
24. Kuhle J, Leppert D, Petzold A, et al. Neurofilament heavy chain in CSF correlates with relapses and disability in multiple sclerosis. Neurology 2011;76:1206-1213.
25. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria. Ann Neurol 2011;69:292-302.
26. Tumani H, Hartung H-P, Hemmer B, et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Disease 2009;35:117-127.
27. Lesko LJ, Atkinson A Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies 1. Annu Rev Pharmacol Toxicol 2001;41:347-366.
28. Frank R, Hargreaves R. Clinical biomarkers in drug discovery and development. Nat Rev Drug Discov 2003;2: 566-580.